Massachusetts Financial Services Co. MA increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,303,272 shares of the company’s stock after acquiring an additional 541,338 shares during the quarter. Johnson & Johnson comprises approximately 1.6% of Massachusetts Financial Services Co. MA’s holdings, making the stock its 8th largest holding. Massachusetts Financial Services Co. MA owned 1.13% of Johnson & Johnson worth $3,676,999,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in JNJ. BlackRock Inc. increased its position in Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after acquiring an additional 7,853,141 shares during the period. Boston Partners boosted its stake in shares of Johnson & Johnson by 68.7% in the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares in the last quarter. Cornerstone Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 10,307.6% in the 2nd quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after purchasing an additional 2,473,105 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Johnson & Johnson by 36.1% in the 2nd quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares in the last quarter. Finally, Summit Trail Advisors LLC boosted its stake in shares of Johnson & Johnson by 11,692.6% in the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,752,841 shares in the last quarter. 66.60% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently commented on JNJ. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Citigroup boosted their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Raymond James boosted their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Finally, HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $142.54.
Shares of NYSE:JNJ opened at $140.68 on Monday. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The firm has a market capitalization of $377.43 billion, a PE ratio of 19.27, a PEG ratio of 2.20 and a beta of 0.58.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.90 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.
In related news, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.